✦ LIBER ✦

50 IMPLEMENTATION OF ADHERENCE TO ERLOTINIB (E) AS SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)

✍ Scribed by V. Gebbia; G. Bellavia; P. Russo; G.L. Banna; F. Ferraù; P. Tralongo; N. Borsellino

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiangiogenic agents as second-line the

✍ Karen L. Reckamp 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 370 KB

Comparison of gefitinib and erlotinib ef

✍ Yu-Yun Shao; Wen-Yi Shau; Zhong-Zhe Lin; Ho-Min Chen; Raymond Kuo; James Chih-Hs 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 943 KB

Clinical effect of erlotinib as first-li

✍ Xin-Hua Xu; Jin Su; Xiang-Yang Fu; Feng Xue; Qiao Huang; Dao-Jun Li; Ming-Qian L 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 232 KB

Factors associated with the likelihood o

✍ Hensing, Thomas A.; Schell, Michael J.; Lee, Ji-Hyun; Socinski, Mark A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Phase-II trial of taxotere (TXT) and Nav

✍ O'Rourke, M.; Garfield, D.; Ellis, P. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Phase II study of weekly paclitaxel as s

✍ Ceresoli, Giovanni Luca; Gregorc, Vanesa; Cordio, Stefano; Bencardino, Katia Bru 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 117 KB